drugset / Trial / NCT07067268
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.
Timeline
- Start
- 2024-09-14
- Primary completion
- 2026-09
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |